Ketamine and the Future of Rapid-Acting Antidepressants
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression within hours of a single administration, even in patients who are considered treatment-resistant. Ketamine is thought to exert these effects by restoring the integrity of neural circuits that are compromised in depression. This hypothesis stems in part from preclinical observations that ketamine can strengthen synaptic connections by increasing glutamate-mediated neurotransmission and promoting rapid neurotrophic factor release. An improved understanding of how ketamine, and other novel rapid-acting antidepressants, give rise to these processes will help foster future therapeutic innovation. Here, we review the history of antidepressant treatment advances that preceded the ketamine discovery, critically examine mechanistic hypotheses for how ketamine may exert its antidepressant effects, and discuss the impact this knowledge has had on ongoing drug discovery efforts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Enhancement in synaptic plasticity is one of the key phenomena that contributes to the antidepressant effects of ketamine (Duman et al., 2016; Riggs & Gould, 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Riggs & Gould, 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 3,320
Research works printed but not linked: 18
- Aguilar-Valles A, 2020, Nature
- Chaturvedi HK, 1999, Indian J. Pharmacol., 31, 104
- Crane GE., 1957, Psychiatr. Res. Rep. Am. Psychiatr. Assoc., 8, 142
- Delgado PL., 2000, J. Clin. Psychiatry, 61, 7
- Demyttenaere K, 2001, J. Clin. Psychiatry, 62, 30
- Hirschfeld RM., 2000, J. Clin. Psychiatry, 61, 4
- Lodge D, 1983, Phencyclidine and Related Arylcyclohexylamines: Present and Future Applications, 595
- Loomer HP, 1957, Psychiatr. Res. Rep. Am. Psychiatr. Assoc., 8, 129
- Mealing G, 1999, J. Pharmacol. Exp. Ther., 288, 204
- Molloy BB, 1994, Pharm. News, 1, 6
- Porsolt RD, 1977, Arch. Int. Pharmacodyn. Ther., 229, 327
- Smith JA., 1953, Am. Pract. Dig. Treat., 4, 519
- Sofia RD, 1975, Arch. Int. Pharmacodyn. Ther., 214, 68
- Stitzel RE., 1976, Pharmacol. Rev., 28, 179
- Trevino K, 2014, Ann. Clin. Psychiatry, 26, 222
- Udenfriend S, 1957, J. Pharmacol. Exp. Ther., 120, 255
- WHO (World Health Organ.), 2017, Depression and Other Common Mental Disorders: Global Health Estimates
- Zeller EA, 1955, Biochem. J., 60, v
Cited by
Sarapultsev, A., Gusev, E., Komelkova, M., Utepova, I., Luo, S., & Hu, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00151-1 · Cited by 221
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Self-citationFrom Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 184
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“We refer the interested reader to a recent detailed review of relevant mechanisms [39].”
BackgroundPositive affect and reward processing in the treatment of depression, anxiety and trauma
Craske, M. G., Dunn, B. D., Meuret, A. E., Rizvi, S. J., & Taylor, C. T. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00355-4 · Cited by 122
“Other glutamate antagonist molecules have failed to show similar effects, and therefore researchers have questioned whether ketamine exerts its effects primarily through glutamate transmission 270 .”
Metadata
- Authors
- Riggs, L. M., & Gould, T. D.
- Affiliations
- University of Maryland, Baltimore (US)
- Venue
- Annual Review of Clinical Psychology
- Publisher
- Annual Reviews
- Published
- 2021-05-07
- Volume
- 17
- Issue
- 1
- Pages
- 207-231
- ISSN
- 1548-5943 (ISSN-L)
- 1548-5951
- PMC
- PMC8170851
- OpenAlex
- W3128979569
- Cited by
- 87
- References
- 144
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 20 · 2023: 22 · 2022: 10 · 2021: 6
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annual Review of Clinical Psychology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs (I01BX004062, I01 BX003631)
- National Institutes of Health (5f31mh123066-02, 2t32ns063391-21)
- National Institute of Mental Health (F31-MH123066, R01MH107615)
- National Institute of General Medical Sciences (T32GM008181, R25GM055036)
- National Institute of Allergy and Infectious Diseases (R21AI145211)
- National Institute of Neurological Disorders and Stroke (T32-NS063391)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, rapid-acting antidepressants, depression, treatment-resistant depression, glutamatergic neurotransmission, synaptic plasticity, neurotrophic factors, antidepressant drug discovery
- MeSH terms
- Antidepressive Agents, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine and the Future of Rapid-Acting Antidepressants. https://app.cochat.ai/papers/10.1146/annurev-clinpsy-072120-014126
- The paper
- Riggs, L. M., & Gould, T. D. (2021). Ketamine and the Future of Rapid-Acting Antidepressants. Annual Review of Clinical Psychology. https://doi.org/10.1146/annurev-clinpsy-072120-014126
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.